Company
Roche Diagnostics
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
101
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
5,238
Received Nov 1, 2025 to Nov 19, 2026
Recall records
392
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Roche Diagnostics, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Roche Diagnostics.
Latest FDA decisions
The 8 newest of 101 since 2015.
- Elecsys HBsAg II quant II RxDxNew device typeDe Novo
DEN260027 · Decided Oct 20, 2026 · 140 days after receipt
Device type: Quantitative Hepatitis B Surface Antigen (SJM) · Laboratory Medicine & Pathology
- Elecsys EBV EBNA IgG510(k)
K260221 · Decided Oct 2, 2026 · 249 days after receipt
Device type: Epstein-Barr Virus, Other (LSE) · Laboratory Medicine & Pathology
- Elecsys EBV VCA IgG510(k)
K260232 · Decided Oct 2, 2026 · 249 days after receipt
Device type: Epstein-Barr Virus, Other (LSE) · Laboratory Medicine & Pathology
98 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
5,238
Received Nov 1, 2025 to Nov 19, 2026. Includes 35 of another or unstated type.
Malfunction reports
5,156
98% of reports
Injury reports
47
0.9% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 365 | 4 | 0 | 0 |
| Jan 24 | 252 | 3 | 0 | 0 |
| Feb 24 | 299 | 0 | 0 | 0 |
| Mar 24 | 323 | 0 | 0 | 0 |
| Apr 24 | 329 | 0 | 0 | 0 |
| May 24 | 305 | 2 | 0 | 0 |
| Jun 24 | 245 | 1 | 0 | 0 |
| Jul 24 | 338 | 1 | 0 | 0 |
| Aug 24 | 296 | 4 | 0 | 0 |
| Sep 24 | 295 | 3 | 0 | 0 |
| Oct 24 | 308 | 2 | 0 | 0 |
| Nov 24 | 305 | 4 | 0 | 0 |
| Dec 24 | 367 | 6 | 0 | 0 |
| Jan 25 | 307 | 0 | 0 | 0 |
| Feb 25 | 281 | 0 | 0 | 0 |
| Mar 25 | 323 | 1 | 0 | 0 |
| Apr 25 | 381 | 0 | 0 | 0 |
| May 25 | 337 | 1 | 1 | 0 |
| Jun 25 | 300 | 3 | 0 | 0 |
| Jul 25 | 364 | 7 | 0 | 0 |
| Aug 25 | 304 | 3 | 0 | 0 |
| Sep 25 | 940 | 2 | 0 | 0 |
| Oct 25 | 429 | 2 | 0 | 0 |
| Nov 25 | 428 | 3 | 0 | 0 |
| Dec 25 | 461 | 3 | 0 | 0 |
| Jan 26 | 319 | 2 | 0 | 0 |
| Feb 26 | 381 | 12 | 0 | 0 |
| Mar 26 | 431 | 2 | 0 | 0 |
| Apr 26 | 495 | 4 | 0 | 0 |
| May 26 | 415 | 5 | 0 | 0 |
| Jun 26 | 454 | 2 | 0 | 0 |
| Jul 26 | 475 | 5 | 0 | 25 |
| Aug 26 | 410 | 0 | 0 | 0 |
| Sep 26 | 448 | 6 | 0 | 0 |
| Oct 26 | 439 | 3 | 0 | 10 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
7 more in this ranking with a free account
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1476-2026 · Started Jan 20, 2026 · Posted by FDA Feb 27, 2026
Reason given: Software defect, which allows the system to accept erroneous, non-monotonous calibrations for Spline-type assays. Cobas pro integrated solutions is an automated analyzer, intended for running qualitative, semi-quantitative and quantitative clinical chemistry and immunochemistry assays, as well as ion-selective...
Cause as FDA categorized it: Software design · Device type: Analyzer, Chemistry (Photometric, Discrete), For Clinical Use (JJE)
Z-1009-2026 · Started Nov 21, 2025 · Posted by FDA Jan 2, 2026
Reason given: Issues identified: 1) Results vary by Instrument Platform; 2) Calibrator Lot-to-Lot Variability. Issues may lead to delayed or incorrect diagnosis, as well as delay of treatment or incorrect treatment.
Cause as FDA categorized it: Process control · Device type: System, Test, Thyroid Autoantibody (JZO)
- cobas HCYS, Homocysteine Enzymatic Assay, Material Number REF 06542921190, for use on cobas c 701/702, in vitro test for total L-homocysteineOpen, Classified
Z-0489-2025 · Started Oct 17, 2024 · Posted by FDA Nov 19, 2024
Reason given: Abnormal calibration signals and control recovery issues on the Homocysteine Enzymatic (HCYS) Assay can produce erroneous patient results (positive or negative bias)
Cause as FDA categorized it: Under Investigation by firm · Device type: Urinary Homocystine (Nonquantitative) Test System (LPS)
389 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.